Skip to main content
Erschienen in: World Journal of Surgery 4/2020

03.01.2020 | Original Scientific Report

Prognostic Nomogram for Resected Pancreatic Adenocarcinoma: A TRIPOD-Compliant Retrospective Long-Term Survival Analysis

verfasst von: Dong Xu, Kai Zhang, Mingna Li, J. P. Neoptolemos, Junli Wu, Wentao Gao, Pengfei Wu, Baobao Cai, Jie Yin, Guodong Shi, Zipeng Lu, Kuirong Jiang, Yi Miao

Erschienen in: World Journal of Surgery | Ausgabe 4/2020

Einloggen, um Zugang zu erhalten

Abstract

Background

Prognostic prediction had been widely used in various cancer entities, from early screening to end-stage patient caring. Currently, there is hardly any well-validated nomogram which exists for long-term survival prediction in pancreatic adenocarcinoma (PC) patients in a post-surgery setting. Our objectives are to identify possible prognostic factors in PC patients following radical resection and to develop a prognostic nomogram based on independent survival predictors.

Methods

From 2009 to 2014, a total of 432 PC patients who underwent curative intended surgeries with complete follow-up data were included in this current retrospective long-term survival analysis. Clinicopathological data were extracted from medical records, and all missing values (percentage 0.9–8.3%) were imputed five times with the “PMM” method. Cox proportional hazards models were utilized. A nomogram was formulated based on results from the multivariate regression model so as to predict OS at 1-, 2- and 3-year as well as median OS. Validations, including discrimination and calibration, were carried out with 1000 bootstrap resamples. External validation was conducted in order to verify the accuracy of our nomogram at 1 and 2 years by utilizing the clinicopathological data of 122 PC patients who underwent curative intended surgeries in 2015 in our centre.

Results

Age, abdominal pain, back pain, tumour location, preoperative neutrophil–lymphocyte ratio, preoperative CA19-9, tumour differentiation, microscopic nerve invasion, microscopic vascular invasion, T stage, lymph node ratio, M stage and adjuvant chemotherapy were all assembled into nomogram. The concordance index (C-index) of internal and external validation was 0.702 and 0.688, respectively. The C-index of the TNM staging system was 0.572 (P < 0.001 vs. nomogram).

Conclusion

Our prognostic nomogram based on clinicopathological parameters shows good performance in long-term survival prediction in PC patients following radical surgery and could play a role in further clinical utilization.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Bailey P, Chang DK, Nones K, Johns AL, Patch AM, Gingras MC et al (2016) Genomic analyses identify molecular subtypes of pancreatic cancer. Nature 531(7592):47–52PubMedCrossRef Bailey P, Chang DK, Nones K, Johns AL, Patch AM, Gingras MC et al (2016) Genomic analyses identify molecular subtypes of pancreatic cancer. Nature 531(7592):47–52PubMedCrossRef
2.
3.
Zurück zum Zitat Neoptolemos JP, Palmer DH, Ghaneh P, Psarelli EE, Valle JW, Halloran CM et al (2017) Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet 389(10073):1011–1024PubMedCrossRef Neoptolemos JP, Palmer DH, Ghaneh P, Psarelli EE, Valle JW, Halloran CM et al (2017) Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet 389(10073):1011–1024PubMedCrossRef
4.
Zurück zum Zitat Hackert T, Strobel O, Michalski CW, Mihaljevic AL, Mehrabi A, Muller-Stich B et al (2017) The TRIANGLE operation—radical surgery after neoadjuvant treatment for advanced pancreatic cancer: a single arm observational study. HPB (Oxford) 19(11):1001–1007CrossRef Hackert T, Strobel O, Michalski CW, Mihaljevic AL, Mehrabi A, Muller-Stich B et al (2017) The TRIANGLE operation—radical surgery after neoadjuvant treatment for advanced pancreatic cancer: a single arm observational study. HPB (Oxford) 19(11):1001–1007CrossRef
5.
Zurück zum Zitat Siegel RL, Miller KD, Jemal A (2016) Cancer statistics, 2016. CA Cancer J Clin 66(1):7–30CrossRef Siegel RL, Miller KD, Jemal A (2016) Cancer statistics, 2016. CA Cancer J Clin 66(1):7–30CrossRef
6.
Zurück zum Zitat Brennan MF, Kattan MW, Klimstra D, Conlon K (2004) Prognostic nomogram for patients undergoing resection for adenocarcinoma of the pancreas. Ann Surg 240(2):293–298PubMedPubMedCentralCrossRef Brennan MF, Kattan MW, Klimstra D, Conlon K (2004) Prognostic nomogram for patients undergoing resection for adenocarcinoma of the pancreas. Ann Surg 240(2):293–298PubMedPubMedCentralCrossRef
7.
Zurück zum Zitat Riley RD, Hayden JA, Steyerberg EW, Moons KG, Abrams K, Kyzas PA et al (2013) Prognosis research strategy (PROGRESS) 2: prognostic factor research. PLoS Med 10(2):e1001380PubMedPubMedCentralCrossRef Riley RD, Hayden JA, Steyerberg EW, Moons KG, Abrams K, Kyzas PA et al (2013) Prognosis research strategy (PROGRESS) 2: prognostic factor research. PLoS Med 10(2):e1001380PubMedPubMedCentralCrossRef
8.
Zurück zum Zitat Moons KG, Royston P, Vergouwe Y, Grobbee DE, Altman DG (2009) Prognosis and prognostic research: what, why, and how? BMJ 338:b375PubMedCrossRef Moons KG, Royston P, Vergouwe Y, Grobbee DE, Altman DG (2009) Prognosis and prognostic research: what, why, and how? BMJ 338:b375PubMedCrossRef
9.
Zurück zum Zitat Kattan MW, Karpeh MS, Mazumdar M, Brennan MF (2003) Postoperative nomogram for disease-specific survival after an R0 resection for gastric carcinoma. J Clin Oncol 21(19):3647–3650PubMedCrossRef Kattan MW, Karpeh MS, Mazumdar M, Brennan MF (2003) Postoperative nomogram for disease-specific survival after an R0 resection for gastric carcinoma. J Clin Oncol 21(19):3647–3650PubMedCrossRef
10.
Zurück zum Zitat Bochner BH, Kattan MW, Vora KC (2006) Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer. J Clin Oncol 24(24):3967–3972PubMedCrossRef Bochner BH, Kattan MW, Vora KC (2006) Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer. J Clin Oncol 24(24):3967–3972PubMedCrossRef
11.
Zurück zum Zitat Weiser MR, Landmann RG, Kattan MW, Gonen M, Shia J, Chou J et al (2008) Individualized prediction of colon cancer recurrence using a nomogram. J Clin Oncol 26(3):380–385PubMedCrossRef Weiser MR, Landmann RG, Kattan MW, Gonen M, Shia J, Chou J et al (2008) Individualized prediction of colon cancer recurrence using a nomogram. J Clin Oncol 26(3):380–385PubMedCrossRef
12.
Zurück zum Zitat Ferrone CR, Kattan MW, Tomlinson JS, Thayer SP, Brennan MF, Warshaw AL (2005) Validation of a postresection pancreatic adenocarcinoma nomogram for disease-specific survival. J Clin Oncol 23(30):7529–7535PubMedPubMedCentralCrossRef Ferrone CR, Kattan MW, Tomlinson JS, Thayer SP, Brennan MF, Warshaw AL (2005) Validation of a postresection pancreatic adenocarcinoma nomogram for disease-specific survival. J Clin Oncol 23(30):7529–7535PubMedPubMedCentralCrossRef
13.
Zurück zum Zitat Hartwig W, Vollmer CM, Fingerhut A, Yeo CJ, Neoptolemos JP, Adham M et al (2014) Extended pancreatectomy in pancreatic ductal adenocarcinoma: definition and consensus of the International Study Group for Pancreatic Surgery (ISGPS). Surgery 156(1):1–14PubMedCrossRef Hartwig W, Vollmer CM, Fingerhut A, Yeo CJ, Neoptolemos JP, Adham M et al (2014) Extended pancreatectomy in pancreatic ductal adenocarcinoma: definition and consensus of the International Study Group for Pancreatic Surgery (ISGPS). Surgery 156(1):1–14PubMedCrossRef
14.
Zurück zum Zitat Bassi C, Marchegiani G, Dervenis C, Sarr M, Abu Hilal M, Adham M et al (2017) The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 years after. Surgery 161(3):584–591PubMedCrossRef Bassi C, Marchegiani G, Dervenis C, Sarr M, Abu Hilal M, Adham M et al (2017) The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 years after. Surgery 161(3):584–591PubMedCrossRef
15.
Zurück zum Zitat Harrell FE Jr, Lee KL, Mark DB (1996) Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 15(4):361–387CrossRef Harrell FE Jr, Lee KL, Mark DB (1996) Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 15(4):361–387CrossRef
16.
Zurück zum Zitat Hanley JA, McNeil BJ (1982) The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 143(1):29–36PubMedCrossRef Hanley JA, McNeil BJ (1982) The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 143(1):29–36PubMedCrossRef
17.
Zurück zum Zitat Heagerty PJ, Lumley T, Pepe MS (2000) Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics 56(2):337–344PubMedCrossRef Heagerty PJ, Lumley T, Pepe MS (2000) Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics 56(2):337–344PubMedCrossRef
18.
Zurück zum Zitat Wan G, Gao F, Chen J, Li Y, Geng M, Sun L et al (2017) Nomogram prediction of individual prognosis of patients with hepatocellular carcinoma. BMC Cancer 17(1):91PubMedPubMedCentralCrossRef Wan G, Gao F, Chen J, Li Y, Geng M, Sun L et al (2017) Nomogram prediction of individual prognosis of patients with hepatocellular carcinoma. BMC Cancer 17(1):91PubMedPubMedCentralCrossRef
19.
Zurück zum Zitat Proctor MJ, McMillan DC, Morrison DS, Fletcher CD, Horgan PG, Clarke SJ (2012) A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer. Br J Cancer 107(4):695–699PubMedPubMedCentralCrossRef Proctor MJ, McMillan DC, Morrison DS, Fletcher CD, Horgan PG, Clarke SJ (2012) A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer. Br J Cancer 107(4):695–699PubMedPubMedCentralCrossRef
20.
Zurück zum Zitat Yang JJ, Hu ZG, Shi WX, Deng T, He SQ, Yuan SG (2015) Prognostic significance of neutrophil to lymphocyte ratio in pancreatic cancer: a meta-analysis. World J Gastroenterol 21(9):2807–2815PubMedPubMedCentralCrossRef Yang JJ, Hu ZG, Shi WX, Deng T, He SQ, Yuan SG (2015) Prognostic significance of neutrophil to lymphocyte ratio in pancreatic cancer: a meta-analysis. World J Gastroenterol 21(9):2807–2815PubMedPubMedCentralCrossRef
21.
Zurück zum Zitat Mowbray NG, Griffith D, Hammoda M, Shingler G, Kambal A, Al-Sarireh B (2018) A meta-analysis of the utility of the neutrophil-to-lymphocyte ratio in predicting survival after pancreatic cancer resection. HPB (Oxford) 20(5):379–384CrossRef Mowbray NG, Griffith D, Hammoda M, Shingler G, Kambal A, Al-Sarireh B (2018) A meta-analysis of the utility of the neutrophil-to-lymphocyte ratio in predicting survival after pancreatic cancer resection. HPB (Oxford) 20(5):379–384CrossRef
22.
Zurück zum Zitat Xu J, Shi KQ, Chen BC, Huang ZP, Lu FY, Zhou MT (2017) A nomogram based on preoperative inflammatory markers predicting the overall survival of pancreatic ductal adenocarcinoma. J Gastroenterol Hepatol 32(7):1394–1402PubMedCrossRef Xu J, Shi KQ, Chen BC, Huang ZP, Lu FY, Zhou MT (2017) A nomogram based on preoperative inflammatory markers predicting the overall survival of pancreatic ductal adenocarcinoma. J Gastroenterol Hepatol 32(7):1394–1402PubMedCrossRef
23.
Zurück zum Zitat Hamada S, Masamune A, Shimosegawa T (2013) Inflammation and pancreatic cancer: disease promoter and new therapeutic target. J Gastroenterol 49(4):605–617PubMedCrossRef Hamada S, Masamune A, Shimosegawa T (2013) Inflammation and pancreatic cancer: disease promoter and new therapeutic target. J Gastroenterol 49(4):605–617PubMedCrossRef
24.
Zurück zum Zitat Sadot E, Basturk O, Klimstra DS, Gonen M, Lokshin A, Do RK et al (2015) Tumor-associated neutrophils and malignant progression in intraductal papillary mucinous neoplasms: an opportunity for identification of high-risk disease. Ann Surg 262(6):1102–1107PubMedPubMedCentralCrossRef Sadot E, Basturk O, Klimstra DS, Gonen M, Lokshin A, Do RK et al (2015) Tumor-associated neutrophils and malignant progression in intraductal papillary mucinous neoplasms: an opportunity for identification of high-risk disease. Ann Surg 262(6):1102–1107PubMedPubMedCentralCrossRef
25.
Zurück zum Zitat Li Y, Sun J, Jiang Z, Zhang L, Liu G (2015) Gemcitabine and S-1 combination chemotherapy versus gemcitabine alone for locally advanced and metastatic pancreatic cancer: a meta-analysis of randomized controlled trials in Asia. J Chemother 27(4):227–234PubMedCrossRef Li Y, Sun J, Jiang Z, Zhang L, Liu G (2015) Gemcitabine and S-1 combination chemotherapy versus gemcitabine alone for locally advanced and metastatic pancreatic cancer: a meta-analysis of randomized controlled trials in Asia. J Chemother 27(4):227–234PubMedCrossRef
26.
Zurück zum Zitat Uesaka K, Boku N, Fukutomi A, Okamura Y, Konishi M, Matsumoto I et al (2016) Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet 388(10041):248–257PubMedCrossRef Uesaka K, Boku N, Fukutomi A, Okamura Y, Konishi M, Matsumoto I et al (2016) Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet 388(10041):248–257PubMedCrossRef
27.
Zurück zum Zitat Hamada C, Okusaka T, Ikari T, Isayama H, Furuse J, Ishii H et al (2017) Efficacy and safety of gemcitabine plus S-1 in pancreatic cancer: a pooled analysis of individual patient data. Br J Cancer 116(12):1544–1550PubMedPubMedCentralCrossRef Hamada C, Okusaka T, Ikari T, Isayama H, Furuse J, Ishii H et al (2017) Efficacy and safety of gemcitabine plus S-1 in pancreatic cancer: a pooled analysis of individual patient data. Br J Cancer 116(12):1544–1550PubMedPubMedCentralCrossRef
28.
Zurück zum Zitat Berger AK, Abel U, Komander C, Harig S, Jager D, Springfeld C (2014) Chemotherapy for advanced pancreatic adenocarcinoma in elderly patients (≥70 years of age): a retrospective cohort study at the National Center for Tumor Diseases Heidelberg. Pancreatology 14(3):211–215PubMedCrossRef Berger AK, Abel U, Komander C, Harig S, Jager D, Springfeld C (2014) Chemotherapy for advanced pancreatic adenocarcinoma in elderly patients (≥70 years of age): a retrospective cohort study at the National Center for Tumor Diseases Heidelberg. Pancreatology 14(3):211–215PubMedCrossRef
29.
Zurück zum Zitat Merkow RP, Bilimoria KY, Tomlinson JS, Paruch JL, Fleming JB, Talamonti MS et al (2014) Postoperative complications reduce adjuvant chemotherapy use in resectable pancreatic cancer. Ann Surg 260(2):372–377PubMedCrossRef Merkow RP, Bilimoria KY, Tomlinson JS, Paruch JL, Fleming JB, Talamonti MS et al (2014) Postoperative complications reduce adjuvant chemotherapy use in resectable pancreatic cancer. Ann Surg 260(2):372–377PubMedCrossRef
30.
Zurück zum Zitat Pu N, Lv Y, Zhao G, Lee W, Nuerxiati A, Wang D et al (2018) Survival prediction in pancreatic cancer patients with no distant metastasis: a large-scale population-based estimate. Future Oncol 14(2):165–175PubMedCrossRef Pu N, Lv Y, Zhao G, Lee W, Nuerxiati A, Wang D et al (2018) Survival prediction in pancreatic cancer patients with no distant metastasis: a large-scale population-based estimate. Future Oncol 14(2):165–175PubMedCrossRef
31.
Zurück zum Zitat Miao Y, Jiang K, Cai B, Yin L, Dai C (2017) Artery divestment for artery involved pancreatic cancer: a retrospective study. Pancreatology 17(4):S25–S26 Miao Y, Jiang K, Cai B, Yin L, Dai C (2017) Artery divestment for artery involved pancreatic cancer: a retrospective study. Pancreatology 17(4):S25–S26
32.
Zurück zum Zitat Showalter TN, Winter KA, Berger AC, Regine WF, Abrams RA, Safran H et al (2011) The influence of total nodes examined, number of positive nodes, and lymph node ratio on survival after surgical resection and adjuvant chemoradiation for pancreatic cancer: a secondary analysis of RTOG 9704. Int J Radiat Oncol Biol Phys 81(5):1328–1335PubMedCrossRef Showalter TN, Winter KA, Berger AC, Regine WF, Abrams RA, Safran H et al (2011) The influence of total nodes examined, number of positive nodes, and lymph node ratio on survival after surgical resection and adjuvant chemoradiation for pancreatic cancer: a secondary analysis of RTOG 9704. Int J Radiat Oncol Biol Phys 81(5):1328–1335PubMedCrossRef
33.
Zurück zum Zitat Elshaer M, Gravante G, Kosmin M, Riaz A, Al-Bahrani A (2017) A systematic review of the prognostic value of lymph node ratio, number of positive nodes and total nodes examined in pancreatic ductal adenocarcinoma. Ann R Coll Surg Engl 99(2):101–106PubMedPubMedCentralCrossRef Elshaer M, Gravante G, Kosmin M, Riaz A, Al-Bahrani A (2017) A systematic review of the prognostic value of lymph node ratio, number of positive nodes and total nodes examined in pancreatic ductal adenocarcinoma. Ann R Coll Surg Engl 99(2):101–106PubMedPubMedCentralCrossRef
34.
Zurück zum Zitat Tarantino I, Warschkow R, Hackert T, Schmied BM, Buchler MW, Strobel O et al (2017) Staging of pancreatic cancer based on the number of positive lymph nodes. Br J Surg 104(5):608–618PubMedCrossRef Tarantino I, Warschkow R, Hackert T, Schmied BM, Buchler MW, Strobel O et al (2017) Staging of pancreatic cancer based on the number of positive lymph nodes. Br J Surg 104(5):608–618PubMedCrossRef
35.
Zurück zum Zitat Tol JA, Gouma DJ, Bassi C, Dervenis C, Montorsi M, Adham M et al (2014) Definition of a standard lymphadenectomy in surgery for pancreatic ductal adenocarcinoma: a consensus statement by the International Study Group on Pancreatic Surgery (ISGPS). Surgery 156(3):591–600PubMedCrossRef Tol JA, Gouma DJ, Bassi C, Dervenis C, Montorsi M, Adham M et al (2014) Definition of a standard lymphadenectomy in surgery for pancreatic ductal adenocarcinoma: a consensus statement by the International Study Group on Pancreatic Surgery (ISGPS). Surgery 156(3):591–600PubMedCrossRef
36.
Zurück zum Zitat Adamska A, Domenichini A, Falasca M (2017) Pancreatic ductal adenocarcinoma: current and evolving therapies. Int J Mol Sci 18(7):1338PubMedCentralCrossRef Adamska A, Domenichini A, Falasca M (2017) Pancreatic ductal adenocarcinoma: current and evolving therapies. Int J Mol Sci 18(7):1338PubMedCentralCrossRef
37.
Zurück zum Zitat Tao L, Yuan C, Ma Z, Jiang B, Xiu D (2017) Surgical resection of a primary tumor improves survival of metastatic pancreatic cancer: a population-based study. Cancer Manag Res 9:471–479PubMedPubMedCentralCrossRef Tao L, Yuan C, Ma Z, Jiang B, Xiu D (2017) Surgical resection of a primary tumor improves survival of metastatic pancreatic cancer: a population-based study. Cancer Manag Res 9:471–479PubMedPubMedCentralCrossRef
Metadaten
Titel
Prognostic Nomogram for Resected Pancreatic Adenocarcinoma: A TRIPOD-Compliant Retrospective Long-Term Survival Analysis
verfasst von
Dong Xu
Kai Zhang
Mingna Li
J. P. Neoptolemos
Junli Wu
Wentao Gao
Pengfei Wu
Baobao Cai
Jie Yin
Guodong Shi
Zipeng Lu
Kuirong Jiang
Yi Miao
Publikationsdatum
03.01.2020
Verlag
Springer International Publishing
Erschienen in
World Journal of Surgery / Ausgabe 4/2020
Print ISSN: 0364-2313
Elektronische ISSN: 1432-2323
DOI
https://doi.org/10.1007/s00268-019-05325-z

Weitere Artikel der Ausgabe 4/2020

World Journal of Surgery 4/2020 Zur Ausgabe

Innovative Surgical Techniques Around the World

Minimally Invasive Pilonidal Excision: Preliminary Report

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.